Novegent, a point of care diagnostic company, announced that, Jian Yuan Holdings have been appointed as its agent in Singapore and the South East Asia market for the COVID19 nucleocapsid protein antigen Test kit. The product has been approved to be sold in Singapore by the Singapore Health Science Authority (HSA) under the Provisional Authorisation in August 2020.
This test kit detects both symptomatic and asymptomatic carriers of the COVID-19 virus (named as SARS-CoV-2 or 2019-nCoV) with results in under 10 minutes from sample of a nasal swab taken. This is one of the fastest, and most sensitive COVID-19 antigen point of care test currently commercially available. In a time when countries are trying to restart from the lockdown, it is a crucial resource to governments as they seek to improve testing capabilities, and have access to rapid, accurate testing technologies.
With fast results, in minutes, instead of hours or days, the Novegent Antigen Test will give infected patients the information they need to get care quickly and limit the amount of time they unknowingly spread the virus to others.
The Company has begun the CE Marking process for this COVID19 Antigen Test Kit to facilitate sales into Europe. It is also in early discussions with numerous countries regulatory bodies including, the U.S. Food and Drug Administration (FDA) for potential release of the test kit under Emergency Use Authorization (EUA).
Separate to this product, Novegent has already developed a complementary COVID19 Antibodies Test Kit that has already been CE Mark since14 May 2020. As a pair, the Novegent antigen and antibody tests kit will give healthcare providers access to testing both for viral presence and also determine if individuals have been exposed to the virus and have developed an antibody response.
The shipment of COVID-19 antigen tests has started and the company is on track to produce half a million tests in October and up to 5 million tests per month by end of the year.
Contact Email: 网信CP551:firstname.lastname@example.org